← Home
Diet Doctor Podcast · March 18, 2024 · 50m
GLP-1 Weight Loss Drugs — Who Benefits and Who Doesn't
Dr. Scher examines GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro) — who truly benefits, the muscle loss problem, cost and sustainability concerns, and why lifestyle interventions should come first for most patients.
Highlights
•
GLP-1 drugs cause 30-40% lean mass loss alongside fat loss — creating worse body composition long-term
Scher: the STEP trials show that 30-40% of weight lost on semaglutide is lean mass (muscle and bone). For patients not doing resistance training, this means worse body composition after treatment — less muscle, same relative fat percentage, lower metabolic rate.•
Lifestyle intervention should be the first prescription for metabolic health — GLP-1 drugs are the second line
Scher: for most patients with metabolic syndrome and obesity, comprehensive lifestyle intervention (diet, exercise, sleep, stress management) addresses the root causes. GLP-1 drugs treat the symptom (weight) without addressing the underlying metabolic dysfunction.